Amendment: SEC Form SCHEDULE 13D/A filed by Clarus Corporation
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 17)
|
CLARUS CORPORATION (Name of Issuer) |
Common Stock, $0.0001 par value (Title of Class of Securities) |
18270P109 (CUSIP Number) |
Robert L. Lawrence Kane Kessler, P.C., 600 3rd Avenue, 35th Floor New York, NY, 10016 (212) 519-5103 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
05/29/2025 (Date of Event Which Requires Filing of This Statement) |

SCHEDULE 13D
|
CUSIP No. | 18270P109 |
1 |
Name of reporting person
Warren B. Kanders | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
PF | ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
UNITED STATES
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
7,073,821.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
17.9 % | ||||||||
14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
CUSIP No. | 18270P109 |
1 |
Name of reporting person
Kanders GMP Holdings, LLC | ||||||||
2 | Check the appropriate box if a member of a Group (See Instructions)
![]() ![]() | ||||||||
3 | SEC use only | ||||||||
4 |
Source of funds (See Instructions)
WC | ||||||||
5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
![]() | ||||||||
6 | Citizenship or place of organization
DELAWARE
| ||||||||
Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
11 | Aggregate amount beneficially owned by each reporting person
1,528,465.00 | ||||||||
12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
![]() | ||||||||
13 | Percent of class represented by amount in Row (11)
3.9 % | ||||||||
14 | Type of Reporting Person (See Instructions)
OO |
SCHEDULE 13D
|
Item 1. | Security and Issuer |
(a) | Title of Class of Securities:
Common Stock, $0.0001 par value |
(b) | Name of Issuer:
CLARUS CORPORATION |
(c) | Address of Issuer's Principal Executive Offices:
2084 East 3900 South, Salt Lake City,
UTAH
, 84124. |
Item 3. | Source and Amount of Funds or Other Consideration |
Item 3 of the Schedule 13D is hereby amended by the addition of the following:
The securities reported in this Amendment No. 17 to Schedule 13D as beneficially owned by the Reporting Person that were acquired since the filing of Amendment No. 16 to Schedule 13D on March 12, 2024 were acquired with funds of approximately $1,239,282. All such funds were provided from the personal funds of the Reporting Person. | |
Item 4. | Purpose of Transaction |
Item 4 of the Schedule 13D is hereby amended to include the following:
On May 29, 2025, the Company delivered a letter (the "Exemption Letter") to Mr. Kanders and his affiliates (collectively, "Kanders") approving the request to be permitted under the Company's Rights Agreement, dated as of February 12, 2008, as amended by Amendment No. 1 thereto dated September 5, 2024, by and between the Company and Equiniti Trust Company, LLC (f/k/a American Stock Transfer and Trust Company) to increase Kanders' beneficial ownership to up to an additional 5,940,700 shares of Common Stock, which when combined with Kanders' current beneficial ownership, would be approximately 32.9% of the Company's outstanding shares of Common Stock. Such approval set forth in the Exemption Letter is conditioned upon, and subject to, among other things: (i) Kanders not increasing his beneficial ownership to in excess of 32.9% of the Company's outstanding shares of Common Stock; and (ii) Kanders increasing his beneficial ownership to up to 32.9% of the Company's outstanding shares of Common Stock, if at all, on or before the twenty-four month anniversary of the date of the Exemption Letter.
Furthermore, in the event that Kanders reduces his beneficial ownership to below 9.9% of the Company's outstanding shares of Common Stock, the Exemption Letter shall immediately terminate and Kanders would need to obtain a new approval from the Company's Board of Directors before seeking to again increase his beneficial ownership to in excess of 9.9% of the Company's outstanding shares of Common Stock.
Mr. Kanders is the Company's Executive Chairman of the Board of Directors and a member of the Company's Board of Directors.
The foregoing description of the Exemption Letter is qualified in its entirety by reference to the full text of the Exemption Letter, which is attached as Exhibit 1 hereto and is incorporated herein by reference. | |
Item 5. | Interest in Securities of the Issuer |
(a) | Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read as follows:
(a) and (b). As of the date of this Schedule 13D, Mr. Kanders may be deemed to be the beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act of 1934, as amended) of 7,073,821 shares of Common Stock, constituting approximately 17.9% of the outstanding shares of Common Stock, which is comprised of: (i) 4,143,927 shares of Common Stock owned directly by Mr. Kanders; (ii) 1,528,465 shares of Common Stock held by Kanders GMP Holdings, LLC ("Holdings"), of which Mr. Kanders is a majority member and a trustee of the manager of Holdings; (iii) options to purchase an aggregate of 1,155,997 shares of Common Stock which were previously granted under the Company's 2015 Stock Incentive Plan and are presently exercisable; (iv) 1,935 shares of Common Stock that Mr. Kanders may be deemed to beneficially own as UTMA custodian for one of his children; (v) 125,221 shares of Common Stock held by Mr. Kanders' spouse in a UTA Trust Account of which Mr. Kanders is the sole trustee; (vi) 17,832 shares of Common Stock that Mr. Kanders may be deemed to beneficially own as joint tenancy with rights of survivorship; and (vii) 100,444 shares of Common Stock that are beneficially owned by Mr. Kanders' spouse. Mr. Kanders (i) has the sole power to direct the vote and disposition of 6,973,377 shares of Common Stock; and (ii) shares with his spouse the power to direct the voting and disposition of 100,444 shares of Common Stock.
The amount reported above as being beneficially owned by Mr. Kanders excludes (i) options to purchase 750,000 shares of common stock that are not presently exercisable and not exercisable within 60 days of the date hereof; (ii) a stock award of 500,000 shares of restricted Common Stock which were previously granted under the Company's 2015 Stock Incentive Plan and all of which shall vest if on or before March 4, 2032, the Fair Market Value (as defined in the 2015 Stock Incentive Plan) of the Common Stock shall have equaled or exceeded $50.00 per share for twenty consecutive trading days; and (iii) a stock award of 500,000 shares of restricted Common Stock which were previously granted under the Company's 2015 Stock Incentive Plan of which (A) 250,000 shares shall vest if on or before March 14, 2033, the Fair Market Value (as defined in the 2015 Stock Incentive Plan) of the Common Stock shall have equaled or exceeded $15.00 per share for twenty consecutive trading days, and (B) 250,000 shares shall vest if on or before March 14, 2033, the Fair Market Value (as defined in the 2015 Stock Incentive Plan) of the Common Stock shall have equaled or exceeded $18.00 per share for twenty consecutive trading days.
The percentage of shares of Common Stock reported as being beneficially owned by Mr. Kanders is based upon 39,557,821 shares of Common Stock outstanding as of the date of this Schedule 13D, which includes: (i) 38,401,824 shares of Common Stock outstanding as of May 1, 2025, as set forth in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Commission on May 8, 2025; and (ii) options to purchase an aggregate of 1,155,997 shares of Common Stock which were previously granted under the Company's 2015 Stock Incentive Plan and that are presently exercisable. |
(b) | The response to Item 5(a) is incorporated herein by reference. |
(c) | No transactions in the shares of the Issuer's Common Stock have been effected by the Reporting Person during the last 60 days. |
(d) | No person, other than the Reporting Person, has the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of the Common Stock reported by this statement, other than the Reporting Person's spouse with respect to the 100,444 shares of Common Stock as to which they have shared voting and dispositive power. |
(e) | N/A |
Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
Item 6 of the Schedule 13D is hereby amended to include the following:
The disclosure set forth in Item 4 of this Schedule 13D with respect to the Exemption Letter is incorporated into this Item 6 by reference. | |
Item 7. | Material to be Filed as Exhibits. |
Item 7 of the Schedule 13D is hereby amended to include the following:
1. Letter to Warren B. Kanders dated May 29, 2025 |
SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|